Illumina, Inc.'s (NASDAQ:ILMN) Price Is Out Of Tune With Revenues
Jan 20
Have your own idea? Try our Stock Screener
U.S. Clinical Research and Equipment Industry Analysis
UpdatedJan 20, 2025
DataAggregated Company Financials
Companies66
- 7D1.5%
- 3M-6.4%
- 1Y-0.1%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has risen 1.5%, driven by gains from Thermo Fisher Scientific of 3.2%. During this same period, the ICON underperformed, falling 9.2%. Despite this gain, the industry's performance has been flat over the past year. As for the next few years, earnings are expected to grow by 17% per annum.
Industry Valuation and Performance
Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 20 Jan 2025 | US$681.4b | US$142.4b | US$10.2b | 43.8x | 66.8x | 4.8x |
| Wed, 18 Dec 2024 | US$666.3b | US$142.3b | US$10.2b | 45.5x | 65.2x | 4.7x |
| Fri, 15 Nov 2024 | US$683.9b | US$142.4b | US$10.3b | 43.5x | 66.4x | 4.8x |
| Sun, 13 Oct 2024 | US$731.7b | US$141.8b | US$8.5b | 37.7x | 86.1x | 5.2x |
| Tue, 10 Sep 2024 | US$739.9b | US$141.8b | US$8.5b | 38.1x | 87.1x | 5.2x |
| Thu, 08 Aug 2024 | US$732.0b | US$141.6b | US$8.6b | 38x | 85.4x | 5.2x |
| Sat, 06 Jul 2024 | US$662.1b | US$141.3b | US$12.2b | 38.8x | 54.4x | 4.7x |
| Mon, 03 Jun 2024 | US$702.1b | US$141.3b | US$12.4b | 38.2x | 56.5x | 5x |
| Wed, 01 May 2024 | US$705.9b | US$141.5b | US$12.7b | 38.4x | 55.5x | 5x |
| Fri, 29 Mar 2024 | US$742.5b | US$142.1b | US$12.8b | 44x | 58x | 5.2x |
| Sun, 25 Feb 2024 | US$729.7b | US$142.1b | US$12.4b | 43.7x | 58.8x | 5.1x |
| Tue, 23 Jan 2024 | US$697.0b | US$153.8b | US$14.2b | 36x | 49.2x | 4.5x |
| Thu, 21 Dec 2023 | US$697.4b | US$153.7b | US$14.2b | 36.8x | 49x | 4.5x |
| Sat, 18 Nov 2023 | US$614.3b | US$153.9b | US$13.9b | 33.5x | 44.2x | 4x |
| Mon, 16 Oct 2023 | US$629.2b | US$154.6b | US$11.2b | 33.2x | 56.2x | 4.1x |
| Wed, 13 Sep 2023 | US$690.0b | US$154.6b | US$11.2b | 32.9x | 61.6x | 4.5x |
| Fri, 11 Aug 2023 | US$730.1b | US$154.7b | US$11.5b | 31.7x | 63.6x | 4.7x |
| Sun, 09 Jul 2023 | US$685.3b | US$152.4b | US$12.5b | 29.6x | 54.8x | 4.5x |
| Tue, 06 Jun 2023 | US$683.0b | US$152.4b | US$12.5b | 29.1x | 54.6x | 4.5x |
| Thu, 04 May 2023 | US$705.3b | US$152.9b | US$9.6b | 28.6x | 73.9x | 4.6x |
| Sat, 01 Apr 2023 | US$728.9b | US$154.6b | US$10.8b | 27x | 67.5x | 4.7x |
| Mon, 27 Feb 2023 | US$712.1b | US$154.3b | US$11.2b | 30.1x | 63.6x | 4.6x |
| Wed, 25 Jan 2023 | US$763.9b | US$155.5b | US$9.0b | 31.1x | 85x | 4.9x |
| Fri, 23 Dec 2022 | US$743.7b | US$155.2b | US$8.8b | 28.6x | 84.7x | 4.8x |
| Sun, 20 Nov 2022 | US$749.5b | US$154.9b | US$8.8b | 27.8x | 84.7x | 4.8x |
| Tue, 18 Oct 2022 | US$693.0b | US$152.5b | US$17.0b | 23.6x | 40.7x | 4.5x |
| Thu, 15 Sep 2022 | US$770.7b | US$152.3b | US$17.3b | 29.4x | 44.5x | 5.1x |
| Sat, 13 Aug 2022 | US$845.8b | US$152.1b | US$17.3b | 32.6x | 49x | 5.6x |
| Mon, 11 Jul 2022 | US$747.5b | US$148.1b | US$20.1b | 31.1x | 37.2x | 5x |
| Wed, 08 Jun 2022 | US$764.0b | US$148.1b | US$20.1b | 31.9x | 38x | 5.2x |
| Fri, 06 May 2022 | US$779.6b | US$151.1b | US$20.9b | 31.7x | 37.3x | 5.2x |
| Sun, 03 Apr 2022 | US$884.8b | US$146.5b | US$25.3b | 36.7x | 34.9x | 6x |
| Tue, 01 Mar 2022 | US$843.6b | US$146.2b | US$25.3b | 37.6x | 33.4x | 5.8x |
| Thu, 27 Jan 2022 | US$807.5b | US$138.0b | US$27.3b | 37.4x | 29.6x | 5.9x |
Price to Earnings Ratio
29.6x
Current Industry PE
- Investors are optimistic on the American Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 66.8x which is higher than its 3-year average PE of 57.8x.
- The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 28% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does U.S. Clinical Research and Equipment compare with similar industries?
| US Market | 3.25% | |
| Healthcare | 0.22% | |
| Life Sciences | 1.45% | |
| Clinical Research and Equipment | 1.45% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | US$559.65 | 0.7% +US$1.6b | 1.1% | PE34.9x | |
| A Agilent Technologies | US$147.36 | 3.8% +US$1.5b | 11.2% | PE32.6x | |
| MTD Mettler-Toledo International | US$1.30k | 2.2% +US$595.3m | 6.3% | PE34.4x | |
| TEM Tempus AI | US$35.15 | 8.7% +US$442.4m | n/a | PS8.6x | |
| STVN Stevanato Group | US$22.85 | 4.2% +US$253.8m | -20.1% | PE52.8x |
